SVShailendra Prasad Verma

Shailendra Prasad Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shailendra Prasad Verma has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    miR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling

    by Surbhi Gupta, Nitu Nigam, Abdullah H. Maad, Ninar AlJerf, S. P. Verma, Swasti Sinha, Rashmi Kushwaha, Manish Kumar Singh, Arun Kumar Trivedi, Soniya Nityanand, et al.

    Background: microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology: We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated miRNAs, and miR-451a was subsequently validated using quantitative real-time PCR (qRT-PCR). Result: The study found that miR-451a was significantly elevated in CML cases compared to controls out of all 450–500 identified miRs. Receiver operating characteristic (ROC) analysis demonstrated moderate predictive performance (AUROC = 0.655), with 76.6% sensitivity and 53.2% specificity at a defined threshold (ΔCt ≥ 1.270). Logistic regression analysis confirmed miR-451a as an independent predictor, with a 16.5% increase in disease odds for each unit (OR = 1.165, p = 0.001). These findings suggest that miR-451a may function as an independent predictor for CML and a valuable molecular marker for disease risk and progression. Conclusion: miR-451a is markedly overexpressed in the peripheral blood of patients with newly diagnosed CML and demonstrates moderate efficacy as a candidate biomarker. Its integration into a multi-marker panel may enhance diagnostic sensitivity and specificity, reinforcing its role in advancing precision medicine approaches in CML.

  • Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia

    by Tuphan Kanti Dolai, Kaustav Ghosh, Biju George, Shipla Roy, Rakhee Kar, Tathagata Chatterjee, Shailendra Prasad Verma, Pankaj Malhotra, Rashmi Kushwaha, Anil Irom Singh, et al.


  • Measurable Residual Disease-Guided Chemotherapy and Transplant-Free Survival in Adult T-ALL -A Single-Centre Experience from North India

    by P. Raghuveer, Shailendra Prasad Verma, Gaurav Datta, Swasti Sinha, Aritra Saha, Alpika Shukla, Akshay Middinti, Rajkumar Maurya

  • Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion

    by Tuphan Kanti Dolai, Rabindra Kumar Jena, Shipla Roy, Maitreyee Bhattacharyya, Amiya Ranjan Nayak, Manoranjan Mahapatra, Kaustav Ghosh, Mukul Aggarwal, Ashish Dixit, Bontha V Babu, et al.

    Thalassemia comprises a heterogeneous group of most common monogenetic disorder and inherited autosomal recessive hemoglobin disorders characterized by defective globin chain synthesis, resulting in hemolysis, ineffective erythropoiesis, chronic anemia, and multisystem complications. India bears a substantial thalassemia burden, with millions of carriers and over 12,000 affected births annually, necessitating standardized, context-appropriate management strategies. These recommendations by the Indian Society of Haematology and Blood Transfusion (ISHBT) provide comprehensive, evidence-informed guidance for the diagnosis, treatment, monitoring, and prevention of thalassemia across diverse healthcare settings in India. The recommendation developed through a structured, multidisciplinary consensus process and expert review, these guidelines aim to harmonize best practices nationwide while allowing flexibility for regional adaptation. Their implementation is expected to improve survival, quality of life, and long-term outcomes for individuals living with thalassemia in India. The guidelines address the clinical spectrum, including transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT), emphasizing early diagnosis through hematological indices, hemoglobin fraction analysis, and molecular testing when indicated. Clear recommendations are provided for rational blood transfusion practices, iron overload monitoring, and timely initiation of iron chelation therapy to prevent cardiac, hepatic, endocrine, and skeletal complications. Disease-specific management of iron-related organ damage, infections, endocrine dysfunction, fertility issues, pregnancy, and emergency scenarios is outlined. Curative and disease-modifying options including hematopoietic stem cell transplantation, gene therapy, and newer agents such as luspatercept, hydroxyurea, and thalidomide are outlined. Preventive strategies, highlighting carrier screening, antenatal and prenatal diagnosis, genetic counseling, and public awareness initiatives.


  • Study of Clinical and Laboratory Profile Of Vitamin B12 Deficiency in Tertiary Health Care Centre in North India

    by Alpika Shukla, Swasti Sinha, Shailendra Prasad Verma, Sumit Rungta, Wahid Ali, Anil Kumar Tripathi, P. Raghuveer, Gaurav Datta, Aritra Saha, Akshay Middinti, et al.

  • Open Access

    Long bone fracture in a child with haemophilia- surgical management under factor coverage: A case report and literature review

    by Suresh Chand, Shailendra Prasad Verma, Praseeth K. Radhakrishnan, Syed Faisal Afaque, Vikas Verma, Rashmi Kushwaha


  • Open Access

    A retrospective analysis of response rates and predictors of response to rituximab in management of primary immune thrombocytopenia: Second line and beyond

    by Shailendra Prasad Verma, Punita Pavecha, Anil Kumar Tripathi, Bhupendra Kumar Singh, Avaneesh Shukla, Durga Prasad Verma, Aparajita Singh Chauhan, Rashmi Kushwaha, Manish Ora

    Objectives: Rituximab is an important second-line option for the treatment of chronic/persistent primary immune thrombocytopenia (ITP). This study aimed to analyze the overall response rates (ORRs) and various factors affecting progression-free survival with rituximab treatment. This can help choose this drug as a second-line option for the best-suited candidates. Material and Methods: We retrospectively analyzed our departmental data of 25 ITP patients treated with rituximab between 2012 and 2020. All patients received rituximab post-first line. Patients with chronic or persistent ITP receiving at least 4 weekly doses of rituximab were included in the study. Patients receiving both low-dose and standard-dose rituximab were included in the study. Results: The median age of patients was 25 years, with a male-female ratio of 1:2. Most patients received rituximab as third-line (56%) or fourth-line (36%) treatment option. Overall, the long-term response rate at a median follow-up of 47.6 months was 60%, while the early response rate at 4 weeks, 8 weeks, and 6 months from the first dose of rituximab was 80%, 60%, and 60%, respectively. Forty per cent of patients could maintain a platelet count >50 × 109/L at 6 months and in the long term. Response at 2 weeks, 4 weeks, early use of rituximab (20 years were associated with significantly better progression-free survival. Conclusion: Rituximab is still a very promising option for primary ITP. Short and definite duration of treatment, good safety profile, and impressive ORRs make this agent a viable option for ITP patients in the current era. Response at 2 weeks, 4 weeks, early use of rituximab (20 years were associated with significantly better progression-free survival.

  • Co-occurrence of hydatid cyst liver with acute myeloid leukaemia: A rare case report

    by Anurag Singh, Anuragani Verma, Rashmi Kushwaha, Uma Shankar Singh, Shailendra Prasad Verma


  • Open Access

    Perioperative management in haemophilia with extended half-life factors: a case series

    by Harshit Khurana, Shailendra Prasad Verma

    Hemophilia B is a hereditary bleeding disorder characterized by deficient or defective coagulation factor IX, leading to a propensity for recurrent bleeding episodes, particularly in the joints. Management of Hemophilia B in surgical settings poses unique challenges due to the risk of excessive bleeding. This paper presents a series of two cases that demonstrate the effective use of perioperative extended half-life (EHL) factor IX products, specifically N9-GP (Refixia), in the surgical management of Hemophilia B. The cases include total knee replacement and total hip replacement. In each case, early initiation of EHL was observed to maintain adequate factor IX levels and control perioperative bleeding effectively, leading to successful surgical outcomes. These findings support the growing body of evidence suggesting the advantages of EHL perioperative treatment in patients with Hemophilia B, particularly in preparation for surgery. The implementation of EHL factor IX products as part of perioperative management plans may contribute to improved surgical outcomes and overall quality of life in Hemophilia B patients.

  • Open Access

    Acute Myeloid Leukaemia With Translocation (8;21) Masquerading as Peripheral Blood Eosinophilia Having Dysplastic Features: A Diagnostic Challenge

    by Anurag Singh, Tanya Tripathi, Akanksha Singh, Sanjay Mishra, Shailendra P. Verma

    Eosinophilia with a modest number of blasts (<20%) in the peripheral blood and bone marrow smears raises suspicion for myeloproliferative neoplasms (MPNs) and acute myeloid leukaemia (AML). Here, we present a case of AML in a 16-year-old boy who presented with high-grade fever, respiratory distress, and generalised weakness. Marked eosinophilia with dysplastic features and occasional blasts were found in the peripheral blood. In view of dysplastic eosinophils and occasional blasts in peripheral blood, a bone marrow examination was requested which revealed increased eosinophils and their progenitors with dysplasia and a modest number of blast cells (<20%). The bone marrow findings suggest MPNs, which were eventually identified as AML having translocation (8;21) with the aid of immunophenotyping and cytogenetic studies. Eosinophilia and its phenotypic anomalies are rarely found in peripheral blood smears of AML patients with translocation (8;21) which may have been related to the leukaemic process.